Kane Biotech Inc. (TSXV:KNE)
Canada · Delayed Price · Currency is CAD 0.0300
+0.0050 (20.00%)
Aug 28, 2026, 2:46 PM EST
Kane Biotech Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.04 | 0.43 | 2.08 | 0.15 | 0.16 | 1.61 | |
Revenue Growth | -97.91% | -79.44% | 1296.75% | -4.95% | -90.25% | 19.84% |
Cost of Revenue | 0.04 | 0.43 | 1.21 | 0.04 | 0.04 | 1.04 |
Gross Profit | -0 | -0 | 0.87 | 0.11 | 0.11 | 0.57 |
Selling, General & Admin | 2.03 | 1.98 | 3.08 | 2.41 | 2.53 | 4.07 |
Research & Development | 0.6 | 0.63 | 1.51 | 1.05 | 1.04 | 1.31 |
Operating Expenses | 2.63 | 2.61 | 4.59 | 3.46 | 3.57 | 5.39 |
Operating Income | -2.63 | -2.61 | -3.72 | -3.35 | -3.46 | -4.82 |
Interest Expense | -0.18 | -0.24 | -0.55 | -1.22 | -0.82 | -0.42 |
Interest & Investment Income | 0.02 | 0.02 | 0 | 0.01 | 0.02 | 0.12 |
Currency Exchange Gain (Loss) | -0 | 0 | -0.01 | 0 | -0.02 | 0 |
EBT Excluding Unusual Items | -2.8 | -2.83 | -4.27 | -4.56 | -4.28 | -5.11 |
Gain (Loss) on Sale of Assets | 0.03 | 0.03 | - | - | - | - |
Asset Writedown | -0.04 | -0.04 | -0.21 | -0.01 | - | -0.07 |
Other Unusual Items | 0.02 | 0.02 | - | 0 | 0.25 | 0.32 |
Pretax Income | -2.8 | -2.83 | -4.47 | -4.56 | -4.02 | -4.85 |
Income Tax Expense | -0.1 | -0.11 | -1.31 | - | - | - |
Earnings From Continuing Operations | -2.7 | -2.72 | -3.16 | -4.56 | -4.02 | -4.85 |
Earnings From Discontinued Operations | - | - | 9.26 | -0.47 | 0.13 | - |
Net Income to Company | -2.7 | -2.72 | 6.1 | -5.03 | -3.89 | -4.85 |
Minority Interest in Earnings | - | - | - | - | - | 0.25 |
Net Income | -2.7 | -2.72 | 6.1 | -5.03 | -3.89 | -4.6 |
Net Income to Common | -2.7 | -2.72 | 6.1 | -5.03 | -3.89 | -4.6 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 161 | 162 | 134 | 127 | 121 | 113 |
Shares Outstanding (Diluted) | 161 | 162 | 155 | 127 | 121 | 113 |
Shares Change | 10.32% | 4.40% | 22.23% | 5.32% | 7.20% | 3.67% |
EPS (Basic) | -0.02 | -0.02 | 0.05 | -0.04 | -0.03 | -0.04 |
EPS (Diluted) | -0.02 | -0.02 | 0.05 | -0.04 | -0.03 | -0.04 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.5 | -3.26 | -4.14 | -2.09 | -3.05 | -2.48 |
Free Cash Flow Per Share | -0.01 | -0.02 | -0.03 | -0.02 | -0.03 | -0.02 |
Gross Margin | -0.04% | -0.15% | 41.91% | 73.48% | 71.48% | 35.36% |
Operating Margin | -6794.22% | -609.87% | -178.66% | -2248.93% | -2206.05% | -299.63% |
Profit Margin | -6980.02% | -636.00% | 293.05% | -3379.05% | -2481.86% | -286.39% |
Free Cash Flow Margin | -6453.52% | -761.99% | -198.77% | -1403.79% | -1947.70% | -153.99% |
EBITDA | -2.63 | -2.55 | -3.62 | -3.23 | -3.3 | -4.73 |
EBITDA Margin | - | - | -174.05% | - | - | -294.36% |
D&A For EBITDA | -0 | 0.06 | 0.1 | 0.12 | 0.16 | 0.08 |
EBIT | -2.63 | -2.61 | -3.72 | -3.35 | -3.46 | -4.82 |
EBIT Margin | - | - | -178.66% | - | - | -299.63% |
Revenue as Reported | 0.43 | 0.43 | 2.08 | 0.15 | 0.16 | 1.61 |